Pear Therapeutics, Inc. announced resignation of Corey McCann, M.D., Ph.D. as President. Christopher D.T. Guiffre, J.D., M.B.A., the Company's Chief Operating Officer, and Chief Financial Officer will serve as the Company's principal executive officer following the departure of Dr. McCann. Dr. McCann will continue to serve as a member of the Board.
Pear Therapeutics, Inc.
Equities
PEAR
US7047231052
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |